Thymosin α-1

The chronic viral hepatitis era is where Thymosin α-1's clinical record was built. Andreone et al. 1996 is the foundational pivotal-era comparator trial — a 33-patient randomization of thymosin α-1 against interferon alfa in anti-HBe-positive HBV-DNA-positive chronic hepatitis B, with thymosin α-1 producing a slower-emerging but more durable response (41.2% complete response at the six-month off-treatment follow-up vs interferon's 25%) and a markedly cleaner tolerability profile. The trial is small by modern standards but anchored the regulatory record that produced the 35-country approval footprint. Camerini & Garaci 2015 — Garaci being the molecule's senior scientific author since the 1980s — synthesises the broader infectious-disease evidence across HBV, HCV, severe sepsis, invasive aspergillosis in bone-marrow-transplant recipients, and vaccine adjunction in immunosenescent older adults. The 2020 Dominari review updates the mechanism and indication picture through the start of the COVID-19 era.

The COVID-19 surge of interest is the largest single pivot the molecule has had in three decades. Liu et al. 2020 — a 76-patient retrospective cohort across two Wuhan hospitals during the first pandemic wave — reported 28-day mortality of 11.1% on thymosin α-1 versus 30.0% in untreated controls (p = 0.044), with the benefit concentrated in patients with the deepest baseline lymphopenia (CD8+ T cells below 400/μL or CD4+ below 650/μL). Mechanistically the treated arm showed restored CD8+ and CD4+ counts, reduced PD-1 and Tim-3 exhaustion markers, and increased TREC-measured thymic output. The result drove inclusion of thymosin α-1 in Chinese national COVID-19 management guidelines and motivated a wave of follow-up studies. The honest read: this is a retrospective cohort, not a randomized trial — clinician-determined treatment assignment, small sample for a mortality endpoint, p-value at the conventional threshold rather than well clear of it, and subsequent meta-analyses have been mixed when restricted to RCT data. It is the largest pivot in clinical attention the molecule has had and the foundational evidence for the long-COVID and post-viral programs that followed, but it is not Phase 3 proof of efficacy.

The newest mechanistic direction is age-related oncology. Wu et al. 2026 tested a rational two-hit strategy in aged-mouse orthotopic hepatocellular carcinoma: IL-15 to rescue peripheral senescent CD8+ T cells, thymosin α-1 to replenish the T-cell pool via thymic rejuvenation. The combination suppressed tumour growth, prolonged survival, reduced the senescent CD8+ T-cell fraction, expanded activated effector populations, and upregulated granzyme B, perforin, and IFN-γ — with PI3K/AKT pathway attenuation as the proposed mechanism (the AKT agonist SC79 abrogated the effect in vitro). The work is preclinical, single-laboratory, and the human component is in-vitro Huh7 co-culture only — but it opens an age-related-cancer / immunosenescence-reversal indication direction that the existing corpus did not cover.

The honest framing rests on three points. First, the 35-country approval footprint paired with zero FDA approval is a regulatory-environment story rather than an efficacy story — the European, Asian, and Latin American regulators reviewed the chronic-hepatitis evidence base and approved on it; the FDA's standard is different and has not been met. Second, the broad-spectrum immunomodulator framing is defensible in the chronic-viral-hepatitis and severe-infection contexts where the underlying biology features T-cell exhaustion and dysregulated innate immunity — those are the settings the trial evidence actually covers. The framing overreaches when extended to the vague "immune boost" marketing that surrounds the molecule in cosmetic-medicine and biohacker contexts. Third, even sympathetic readers of the geroprotective literature on related thymic peptides (the Khavinson & Morozov 2002 / 2003 thymalin / epithalamin work) should note that those studies used polypeptide fractions from calf thymus and pineal gland rather than synthetic thymosin α-1 specifically — the geroprotective inference onto the modern molecule is one mechanistic step removed from what the underlying cohort actually measured.